Statements (35)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:contrast_agent
|
| gptkbp:administeredBy |
intravenous injection
|
| gptkbp:alternativeTo |
iodinated contrast agents
|
| gptkbp:approvedBy |
gptkb:FDA
1988 |
| gptkbp:can_accumulate_in |
bone tissue
brain tissue |
| gptkbp:cause |
allergic reactions
mild side effects (nausea, headache, dizziness) rare severe reactions (anaphylaxis) |
| gptkbp:chemical_form |
chelated gadolinium
|
| gptkbp:contains |
gptkb:gadolinium
|
| gptkbp:contraindication |
severe renal impairment
|
| gptkbp:crosses |
blood-brain barrier (if disrupted)
|
| gptkbp:excretion |
kidneys
|
| gptkbp:halfLife |
1.5 hours (in normal renal function)
|
| gptkbp:improves |
MRI images
|
| gptkbp:marketedAs |
gptkb:Gadovist
gptkb:Magnevist MultiHance Omniscan ProHance Dotarem |
| gptkbp:notRecommendedFor |
pregnant women (unless essential)
breastfeeding women (use with caution) |
| gptkbp:regulates |
gptkb:FDA
gptkb:EMA |
| gptkbp:riskFactor |
gptkb:nephrogenic_systemic_fibrosis
|
| gptkbp:used_in |
magnetic resonance imaging
|
| gptkbp:usedFor |
musculoskeletal imaging
vascular imaging CNS imaging |
| gptkbp:bfsParent |
gptkb:T1_space
|
| gptkbp:bfsLayer |
8
|
| https://www.w3.org/2000/01/rdf-schema#label |
gadolinium contrast
|